MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$336K
Free Cash flow
-$3,564K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of debt
Proceeds from issuance of prefer...
Proceeds from issuance of warran...
Others
Negative Cash Flow Breakdown
Net loss
Reduction of debt liability
Proceeds from exercise of warran...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-5,523
-7,751
-6,954
-14,276
Stock-based compensation expense
50
151
47
55
Depreciation and amortization
511
454
-
-
Fair value of common stock issued for services
72
514
-
-
Paid-in-kind interest expense on promissory note
-
40
-
100
Depreciation and amortization
-
-
442
384
Accounts receivable
-331
188
-553
501
Operating lease liabilities, net
49
18
129
-7
Prepaid expenses and other current assets
61
166
209
-130
Deposits and other
18
26
19
16
Accounts payable
950
318
-424
340
Accrued expenses
929
125
3,303
442
Other liabilities
-386
385
-521
358
Contract liability
88
16
-59
53
Net cash used in operating activities
-3,148
-6,010
-3,812
-4,161
Payment for acquisition, net of excess cash of 865
-
-
-
0
Acquisitions of property and equipment
416
18
1,531
-83
Cash paid for acquisition of scn
-
-
5,185
-
Net cash used in investing activities
-416
-18
-1,581
83
Proceeds from issuance of debt
1,625
1,400
1,448
-417
Proceeds from issuance of common stock
291
342
2,801
2,428
Proceeds from issuance of preferred stock
1,105
-
-
-
Proceeds from issuance of warrants
995
567
0
1,699
Proceeds from issuance of pre-funded warrants
0
68
0
0
Proceeds from exercise of warrants
-447
4,639
0
-833
Payments for issuance costs
-
487
0
0
Reduction of debt liability
814
309
-
97
Payments for finance lease liability
14
14
11
17
Net cash provided by financing activities
3,228
6,109
4,335
2,763
Net (decrease) increase in cash and cash equivalents
-336
81
-1,058
-1,315
Cash and cash equivalents at beginning of year
2,110
2,029
3,087
6,260
Cash and cash equivalents at end of period
1,774
2,110
2,029
3,087
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
debt
$1,625K
(-83.15%↓ Y/Y)
Proceeds from issuance of
preferred stock
$1,105K
Proceeds from issuance of
warrants
$995K
(-41.44%↓ Y/Y)
something is missing
$487K
Proceeds from issuance of
common stock
$291K
(-16.14%↓ Y/Y)
Net cash provided by
financing activities
$3,228K
(-71.83%↓ Y/Y)
Canceled cashflow
$1,275K
Net (decrease)
increase in cash and cash...
-$336K
(81.92%↑ Y/Y)
Canceled cashflow
$3,228K
Accounts payable
$950K
(56.25%↑ Y/Y)
Accrued expenses
$929K
(831.50%↑ Y/Y)
Depreciation and
amortization
$511K
(5.80%↑ Y/Y)
Accounts receivable
-$331K
(-223.05%↓ Y/Y)
Contract liability
$88K
(117.32%↑ Y/Y)
Fair value of common
stock issued for...
$72K
Stock-based compensation
expense
$50K
(-91.06%↓ Y/Y)
Operating lease
liabilities, net
$49K
(173.13%↑ Y/Y)
Reduction of debt
liability
$814K
Proceeds from exercise of
warrants
-$447K
(-126.31%↓ Y/Y)
Payments for finance
lease liability
$14K
Net cash used in
operating activities
-$3,148K
(56.82%↑ Y/Y)
Canceled cashflow
$2,980K
Net cash used in
investing activities
-$416K
(93.10%↑ Y/Y)
Net loss
-$5,523K
(37.78%↑ Y/Y)
Other liabilities
-$386K
(-159.75%↓ Y/Y)
Prepaid expenses and
other current assets
$61K
(162.24%↑ Y/Y)
Deposits and other
$18K
(128.13%↑ Y/Y)
Acquisitions of property and
equipment
$416K
(-53.42%↓ Y/Y)
Buy us a coffee
Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc. (VVOS)